{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-100080","form_type":"8-K","ticker":"BNTC","cik":"0001808898","company_name":"Benitec Biopharma Inc.","filed_at":"2024-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.241615+00:00","generated_at":"2026-06-03T19:21:24.695934+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Benitec reports positive interim clinical data for BB-301 in OPMD first subject at 90 days","bullets":["First subject showed improvements in videofluoroscopic swallowing studies and Sydney Swallow Questionnaire at Day 90 vs. pre-dose baseline.","No serious adverse events observed; two subjects had transient Grade 2 GERD that resolved with standard medication.","BB-301 is a gene therapy for OPMD, affecting ~15,000 patients worldwide; has FDA and EMA Orphan Drug designation.","Data from 90-day timepoint demonstrated improvement over initial natural history measurements taken >12 months prior."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-100080","json":"https://secwatch.observer/filing/0001193125-24-100080.json","markdown":"https://secwatch.observer/filing/0001193125-24-100080.md","text":"https://secwatch.observer/filing/0001193125-24-100080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/0001193125-24-100080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1808898/000119312524100080/d815188d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T19:21:24.695934+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}